In a report published Friday, Stifel analyst Stephen Willey terminated coverage on Onyx Pharmaceuticals ONXX.
In the report, Stifel noted, “We are discontinuing coverage of Onyx Pharmaceuticals due to the company's acquisition by Amgen (AMGN, Covered by our Colleague Joel Sendek, Hold, $115.41) at $125.00 per share in cash. Our last rating on the stock was Hold. Our FY13 estimates for ONXX were EPS of $(2.92) and $626M of revenues.”
Onyx Pharmaceuticals closed on Thursday at $124.70.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in